Recombinant Anti-E Cadherin antibody [EPR16845-108] (ab181296)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR16845-108] to E Cadherin
- Suitable for: WB, IP
- Reacts with: Mouse, Rat
Related conjugates and formulations
Overview
-
Product name
Anti-E Cadherin antibody [EPR16845-108]
See all E Cadherin primary antibodies -
Description
Rabbit monoclonal [EPR16845-108] to E Cadherin -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details -
Species reactivity
Reacts with: Mouse, Rat -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: His-tagged mouse E-Cadherin active protein (aa1-709); Rat spleen lysate; Mouse plasma and serum; Mouse brain lysate. IP: Mouse serum.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 0.05% BSA, 40% Glycerol, PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR16845-108 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab181296 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Detects a band of approximately 120, 84 kDa (predicted molecular weight: 97 kDa).
|
|
IP |
1/30.
|
Notes |
---|
WB
1/1000. Detects a band of approximately 120, 84 kDa (predicted molecular weight: 97 kDa). |
IP
1/30. |
Target
-
Function
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7.
E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production. -
Tissue specificity
Non-neural epithelial tissues. -
Involvement in disease
Defects in CDH1 are the cause of hereditary diffuse gastric cancer (HDGC) [MIM:137215]. An autosomal dominant cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations in the has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.
Defects in CDH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
Defects in CDH1 are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. -
Sequence similarities
Contains 5 cadherin domains. -
Post-translational
modificationsDuring apoptosis or with calcium influx, cleaved by a membrane-bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 to produce fragments of about 38 kDa (E-CAD/CTF1), 33 kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. Processing by the metalloproteinase, induced by calcium influx, causes disruption of cell-cell adhesion and the subsequent release of beta-catenin into the cytoplasm. The residual membrane-tethered cleavage product is rapidly degraded via an intracellular proteolytic pathway. Cleavage by caspase-3 releases the cytoplasmic tail resulting in disintegration of the actin microfilament system. The gamma-secretase-mediated cleavage promotes disassembly of adherens junctions. -
Cellular localization
Cell junction. Cell membrane. Endosome. Golgi apparatus > trans-Golgi network. Colocalizes with DLGAP5 at sites of cell-cell contact in intestinal epithelial cells. Anchored to actin microfilaments through association with alpha-, beta- and gamma-catenin. Sequential proteolysis induced by apoptosis or calcium influx, results in translocation from sites of cell-cell contact to the cytoplasm. Colocalizes with RAB11A endosomes during its transport from the Golgi apparatus to the plasma membrane. - Information by UniProt
-
Database links
- Entrez Gene: 12550 Mouse
- Entrez Gene: 83502 Rat
- SwissProt: P09803 Mouse
- SwissProt: Q9R0T4 Rat
- Unigene: 35605 Mouse
- Unigene: 1303 Rat
-
Alternative names
- Arc 1 antibody
- CADH1_HUMAN antibody
- Cadherin 1 antibody
see all
Images
-
Lane 1 : Anti-E Cadherin antibody [EPR16845-108] (ab181296) at 1/20000 dilution
Lane 2 : Anti-E Cadherin antibody [EPR16845-108] (ab181296) at 1/100000 dilution
All lanes : His-tagged mouse E-Cadherin active protein (aa1-709)
Lysates/proteins at 0.01 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 97 kDa
Observed band size: 120,84 kDa why is the actual band size different from the predicted?
Exposure time: 10 seconds -
All lanes : Anti-E Cadherin antibody [EPR16845-108] (ab181296) at 1/1000 dilution
Lane 1 : Rat spleen lysate
Lane 2 : Mouse plasma
Lane 3 : Mouse serum
Lane 4 : Mouse brain lysate
Lysates/proteins at 10 µg per lane.
Secondary
Lanes 1 & 4 : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Lanes 2-3 : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
Developed using the ECL technique.
Predicted band size: 97 kDa
Observed band size: 120,84 kDa why is the actual band size different from the predicted?Exposure time : Lanes 1-2: 30 seconds; Lanes 3-4: 15 seconds.
Blocking/Dilution buffer: 5% NFDM/TBST.
The expression profile observed is consistent with what has been described in the literature (PMID: 11076937; PMID: 11953314).
-
E Cadherin was immunoprecipitated from 1 mg of mouse serum with ab181296 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab181296 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1: Mouse serum 10 µg (Input).
Lane 2: ab181296 IP in mouse serum.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab181296 in mouse serum.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 1 second.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (4)
ab181296 has been referenced in 4 publications.
- Ye J et al. MicroRNA‑671‑5p inhibits cell proliferation, migration and invasion in non‑small cell lung cancer by targeting MFAP3L. Mol Med Rep 25:N/A (2022). PubMed: 34841435
- Jia M et al. Inhibition of PI3K/AKT/mTOR Signalling Pathway Activates Autophagy and Suppresses Peritoneal Fibrosis in the Process of Peritoneal Dialysis. Front Physiol 13:778479 (2022). PubMed: 35309056
- Tan Q et al. VEGF-B targeting by aryl hydrocarbon receptor mediates the migration and invasion of choriocarcinoma stem-like cells. Cancer Cell Int 22:221 (2022). PubMed: 35773697
- Zhu Z et al. Gut microbiota regulate tumor metastasis via circRNA/miRNA networks. Gut Microbes 12:1788891 (2020). PubMed: 32686598